Bengaluru-based Ayati Devices secured ₹15 crore in a Pre-Series A round, its first institutional investment. The funding aims to push its diabetic foot complication diagnostics beyond tertiary hospitals to primary care centers. For diabetes patients in Tier-2 cities, this means earlier, more affordable screening access.
How We Got Here
Ayati, incubated at IITB-SINE, has focused on developing portable diagnostic tools for preventative diabetic foot care. Inflexor Ventures' investment marks the company's crucial first institutional funding round.
The Numbers
- Ayati Devices' portfolio includes Vibrasense for neuropathy and Vasosense for peripheral artery disease screening.
- Mumbai-based Nexular, founded in 2023 by Sweden-trained Joel and Emma Rozada, builds EV connectivity and remote vehicle management.
- Vecton AI secured ₹6 crore pre-seed from Zeropearl VC, leveraging an FDE model for enterprise AI in BFSI.
- Nexular ensures data privacy and regulatory compliance by storing vehicle data on private local servers.
What Happens Next
🇮🇳 Why This Matters for India
Ayati's focus on portable diagnostics takes preventative diabetic foot care beyond metros, directly impacting rural patients and smaller clinics.
The Take
What's often missed in these funding rounds is the consistent bet on B2B deep tech solving core infrastructure gaps, not just consumer apps. This indicates investors are shifting from the 'app economy' to foundational tech plays across critical sectors.
Source:
YourStory ↗